NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-.

Cover of Drugs and Lactation Database (LactMed)

Drugs and Lactation Database (LactMed) [Internet].

Show details

Fingolimod

Last Revision: May 17, 2021.

Estimated reading time: 1 minute

CASRN: 162359-55-9

image 135204658 in the ncbi pubchem database

Drug Levels and Effects

Summary of Use during Lactation

Although fingolimod and its active metabolite are highly bound in maternal plasma and unlikely to reach the breastmilk in large amounts, it is potentially toxic to the breastfed infant. Because there is no published experience with fingolimod during breastfeeding, expert opinion generally recommends that it should be avoided during breastfeeding, especially while nursing a newborn or preterm infant.[1-6] However, the manufacturer's labeling does not recommend against its use in breastfeeding.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Alternate Drugs to Consider

(Multiple Sclerosis) Glatiramer, Immune Globulin, Interferon Beta

References

1.
Bove R, Alwan S, Friedman JM, et al. Management of multiple sclerosis during pregnancy and the reproductive years: A systematic review. Obstet Gynecol. 2014;124:1157–68. [PubMed: 25415167]
2.
Cree BA. Update on reproductive safety of current and emerging disease-modifying therapies for multiple sclerosis. Mult Scler. 2013;19:835–43. [PubMed: 23319073]
3.
Houtchens MK, Kolb CM. Multiple sclerosis and pregnancy: Therapeutic considerations. J Neurol. 2013;260:1202–14. [PubMed: 22926165]
4.
Almas S, Vance J, Baker T, et al. Management of multiple sclerosis in the breastfeeding mother. Mult Scler Int. 2016;2016:6527458. [PMC free article: PMC4757692] [PubMed: 26966579]
5.
Kaplan TB. Management of demyelinating disorders in pregnancy. Neurol Clin. 2019;37:17–30. [PubMed: 30470273]
6.
Dobson R, Dassan P, Roberts M, et al. UK consensus on pregnancy in multiple sclerosis: 'Association of British Neurologists' guidelines. Pract Neurol. 2019;19:106–14. [PubMed: 30612100]

Substance Identification

Substance Name

Fingolimod

CAS Registry Number

162359-55-9

Drug Class

Breast Feeding

Lactation

Immunosuppressive Agents

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Views

Related information

Similar articles in PubMed

  • Review Siponimod[Drugs and Lactation Database (...]
    Review Siponimod
    . Drugs and Lactation Database (LactMed). 2006
  • Review Ozanimod[Drugs and Lactation Database (...]
    Review Ozanimod
    . Drugs and Lactation Database (LactMed). 2006
  • Review Dasatinib[Drugs and Lactation Database (...]
    Review Dasatinib
    . Drugs and Lactation Database (LactMed). 2006
  • Review Butorphanol[Drugs and Lactation Database (...]
    Review Butorphanol
    . Drugs and Lactation Database (LactMed). 2006
  • Review Chloroprocaine[Drugs and Lactation Database (...]
    Review Chloroprocaine
    . Drugs and Lactation Database (LactMed). 2006
See reviews...See all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...